Download Free Medical Pharmacogenomics Based Personalized Medicine PowerPoint Presentation

Pharmacogenomics Based Personalized Medicine PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Pharmacogenomics based personalized medicine" by Devender S. Dhanda MS MBA, Greg F. Guzauskas MPH PhD, and David L. Veenstra PharmD PhD.
This medical PowerPoint presentation discusses how Pharmacogenomics is the study of how an individuals genes affect their response to drugs, and how by analyzing a persons genetic makeup, doctors can identify which medications are likely to be most effective for them and which may cause unwanted side effects.

Tags : Pharmacogenomics, genetic variations, pharmacology, genomics, Genetics, Genetics PowerPoint presentation

Published on : Mar 27, 2023 | Views : 1107 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine? Devender S. Dhanda MS MBA, Greg F. Guzauskas MPH PhD, David L. Veenstra PharmD PhD Pharmaceutical Outcomes Research and Policy Program University of Washington, Seattle, WA, USA 1
Slide 2-

Personalized Medicine: Will There be a Right Time to Implement? Over 140 US FDA approved drugs have PGx information on labels Up to 50% of drugs under development – associated biomarker program2 Fewer than 10% of drugs will be launched with companion diagnostics –potential risks for PGx evidence generation & reimbursement bottlenecks2 Issue more prominent for germline variations used to inform usage of existing off-patent drugs – ownership of evidence generation issues Drugs – pathways of evidence generation and reimbursement systems Pharmacogenomics Tests – uncertainty regarding level of evidence and who is responsible for evidence generation 2 1 Faulkner et al A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health 15 (2012) 1162-1171 2 Davis et al.The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise.Nat Rev Drug Discov.2009;8(4):279–86
Slide 3-

Pharmacogenomics = “Insufficient evidence”? Genomics information similar to other medical/health information EGAPP working group – 6 out of 8 evaluations have “insufficient evidence” 3 Clinicians/consumers/policy makers frustrated and still have to make decisions based on insufficient evidence 1 Should we defer the decision-making in clinical practice until sufficient evidence - may take decades (Khoury et al) and millions of dollars? 2 3 1 ttp://www.egappreviews.org/recommendations/index.htm accessed on 09/25/2015 2 Khoury et al. Evidence-based classification of recommendations on use of genomic tests in clinical practice: Dealing with insufficient evidence Genetics in Medicine (2010) 12, 680–683 Personalized Medicine: Will There be a Right Time to Implement?
Slide 4-

Warfarin Case study Widely prescribed for prevention of thromboembolic events Narrow therapeutic index Up to 20-fold inter-individual dose variation Partly due to gene variations in CYP2C9 and VKORC1 difficult to determine the exact dose Under dosing –Thrombo-embolic events (TEs) Overdosing –Bleed events Interacts with more than 800 drugs Interaction with Amiodarone due to inhibition of CYP2C9 Amiodarone increases the levels of warfarin resulting in bleed events 4
Slide 5-

Warfarin Case Study:A Tale of Two Scenarios Pharmacogenomic Scenario Exposure = CYP2C9 and VKORC1 gene variants Recommendation – Insufficient evidence DDI Scenario Exposure = Amiodarone (CYP2C9 inhibitor) Recommendation – Standard of care 5 The 8th American Academy of Chest physicians (ACCP) Guidelines state, “…without evidence from randomized trials, we suggest against the use of pharmacogenetics-based initial dosing.3” The ACCP Guidelines state, “…in patients who are taking medications known to increase sensitivity to warfarin (e.g., amiodarone), we recommend the use of a starting dose <5mg. 3” 3 Antithrombotic and Thrombolytic Therapy, 8th Ed : ACCP Guidelines: ANTITHROMBOTIC AND THROMBOLYTIC THERAPY, 8TH ED: ACCP GUIDELINES | June 2008
Slide 6-

Value of Information (VOI) Analysis: Uncertainty Estimation for Evidence Levels VOI is a reflection of current evidence in a decision problem as well as the value of collecting future evidence We propose to utilize VOI to quantitatively estimate the evidence levels given the current uncertainty in the PGx and DDI evidence for warfarin (EVPI as an indicator of uncertainty) Objective: To quantitatively compare the evidence levels of a PGx –based scenario to its analogous clinical based scenario utilizing the VOI analysis. 6
Slide 7-

Methods 7
Slide 8-

Two Markov Models – PGx and DDI Both the models are analogous Difference in inputs - RR-Bleed, RR-Clot, and cost of amiodarone and cost of PGx test 8 Warfarin PGx Dosing Model Warfarin – Amiodarone (DDI Model)
Slide 9-

9 Brown et al Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues: Meta-analysis of Randomized Clinical Trials – JAMA August 2014
Slide 10-

10
Slide 11-

11 PGx Test Cost - $175 PGx Test Cost - $175
Slide 12-

Expected Value of Partial Perfect Information (EVPPI) for PGx and DDI 12
Slide 13-

13
Slide 14-

Conclusions The evidence levels for warfarin pharmacogenomics and warfarin-amiodarone DDI appear to be similar The value of perfect information is higher for DDI because of greater uncertainty in the stroke risk due to dose reduction of warfarin The value of perfect information is higher for higher PGx test cost Main contributors of uncertainty for both PGx and DDI – bleed and stroke risk Our findings suggest that policies for implementation of pharmacogenomics-based testing should be comparable to the DDI-based clinical decisions, which is not the case currently in both clinical and reimbursement guidelines 14
Slide 15-

Acknowledgements Personalized Medicine Economics Research (PriMER) grant Dr. David Veenstra PharmD, PhD Dr. Anirban Basu PhD Dr. Josh Carlson MPH, PhD Greg Guzauskas MPH, PhD 15
Slide 16-

AppendixSlides 16
Slide 17-

Probability of Making Optimal Decision PGx Test cost- $175 17
Slide 18-

Probability of Making Optimal Decision Decreases with Higher PGx Test Cost 18
Slide 19-

19
Slide 20-

20
Slide 21-

21
Slide 22-

22 CYP2C9 and VKORC1 Variants (PGx Model) Amiodarone (DDI Model)